Patients’ self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study
-
Published:2022-12-16
Issue:1
Volume:6
Page:
-
ISSN:2509-8020
-
Container-title:Journal of Patient-Reported Outcomes
-
language:en
-
Short-container-title:J Patient Rep Outcomes
Author:
Hong Sung-Hoo, Chung Ho Seok, Seo Ill-Young, Kwon Tae Gyun, Jeong Hyeon, Chung Jae-Il, Jeon Seung Hyun, Park Jae Young, Ha Hong Koo, Chung Byung-Ha, Song Wan, Kim Young-Joo, Kim Sang-Hee, Lee Jee-Sun, Lee Juneyoung, Chung JinsooORCID
Abstract
Abstract
Background
Early intervention to reduce the impact of adverse events (AEs) may improve patients’ quality of life and enable optimal treatment duration.
Methods
This nationwide, multicenter, prospective, longitudinal, 1-year observational study investigated patients’ self-management of AEs associated with targeted therapy for advanced renal cell carcinoma (RCC) and explored corresponding outcomes, including treatment duration and patient-reported outcomes (PROs).
Results
We enrolled 77 advanced RCC patients (mean age 62 years) treated with a first targeted therapy. 210 cases of seven AEs of interest (fatigue, hand-foot syndrome, oral mucosal inflammation, diarrhea, gastrointestinal symptoms, hypertension, and anorexia) were observed. Most AEs were mild to moderate. Overall, 63.4% of patients were identified as managing their AEs well, reporting numerically longer treatment duration and significantly higher PRO scores than patients identified as poor managers.
Conclusions
Longer treatment duration and improved PROs were observed when advanced RCC patients managed targeted therapy-associated AEs well. Repeated education for consolidating AE self-management could be considered to enhance overall treatment outcomes.
Funder
Pfizer Pharmaceuticals Korea
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference21 articles.
1. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, Hammond LJ, Zuccarino-Catania G (2019) NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw 17(11):1278–1285. https://doi.org/10.6004/jnccn.2019.0054 2. Miyake H, Harada K, Inoue TA, Fujisawa M (2014) Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors. Med Oncol 31(9):190. https://doi.org/10.1007/s12032-014-0190-6 3. Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A, Pérez Valderrama B, Viciana R (2012) Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31(Suppl 1):S19–S27. https://doi.org/10.1007/s10555-012-9355-y 4. Eberhardt-Wetherington B, Gall V, Lang M, Schmidinger M, Gruenwald V, Claussen C, Wartenberg M, Niedtner R, Kalanovic D (2013) Patient and physician perspective on published therapy management recommendations for TKI-treated patients with a focus on sunitinib: The TheMaPaC project (Therapy Management Patient Consensus). J Clin Oncol 31(6_suppl):445 5. Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS (2012) Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 29(2):786–794. https://doi.org/10.1007/s12032-011-9922-z
|
|